C K, Surie D, Lauring A, Martin E, Leis A, Papalambros L, Gaglani M, Columbus C, Gottlieb R, Ghamande S, Peltan I, Brown S, Ginde A, Mohr N, Gibbs K, Hager D, Saeed S, Prekker M, Gong M, Mohamed A, Johnson N, Srinivasan V, Steingrub J, Khan A, Hough C, Duggal A, Wilson J, Qadir N, Chang S, Mallow C, Kwon J, Parikh B, Exline M, Vaughn I, Ramesh M, Safdar B, Mosier J, Harris E, Shapiro N, Felzer J, Zhu Y, Grijalva C, Halasa N, Chappell J, Womack K, Rhoads J, Baughman A, Swan S, Johnson C, Rice T, Casey J, Blair P, Han J, Ellington S, Lewis N, Thornburg N, Paden C, Atherton L, Self W, Dawood F, DeCuir J. Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity—IVY Network, 26 Hospitals, October 18, 2023–March 9, 2024. Clinical Infectious Diseases 2024, ciae405. PMID: 39107255, DOI: 10.1093/cid/ciae405.Peer-Reviewed Original Research